Biblio
Correction: The YAP1 Signaling Inhibitors, Verteporfin and CA3, Suppress the Mesothelioma Cancer Stem Cell Phenotype. Mol Cancer Res. 2023;21(9):991.
. Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors. Eur J Med Chem. 2022;232:114172.
. Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity. Mol Carcinog. 2021.
. Suppressing AP1 Factor Signaling in Suprabasal Epidermis Produces A Keratoderma Phenotype. J Invest Dermatol. 2014.
. Transglutaminase 2 binds to the CD44v6 cytoplasmic domain to stimulate CD44v6/ERK1/2 signaling and maintain an aggressive cancer phenotype. Mol Cancer Res. 2023.
. Transglutaminase 2 takes center stage as a cancer cell survival factor and therapy target. Mol Carcinog. 2019.
. Transglutaminase is a tumor cell and cancer stem cell survival factor. Mol Carcinog. 2015.
. TRANSGLUTAMINASE IS REQUIRED FOR EPIDERMAL SQUAMOUS CELL CARCINOMA STEM CELL SURVIVAL. Mol Cancer Res. 2015.
.